Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Document › Details

Kiadis Pharma N.V.. (5/30/19). "Press Release: Kiadis Pharma Launches a Private Placement of New Shares to Raise approximately EUR 25 Million [Not for US, AU, CA, JP, ZA, et al.]". Amsterdam.

	Organisation	Kiadis Pharma N.V. (Euronext: KDS)
	Group	Kiadis (Group)
	Organisation 2	Piper Jaffray & Co. (NYSE: PJC)
	Today	Piper Sandler Companies (NYSE: PIPR)
	Group	Piper Sandler (Group)
	Product	ATIR101™ (Kiadis)
	Product 2	investment banking
	Index term	Kiadis–SEVERAL: investment, 201905 private placment €27.6m with 3.68m new shares at €7.5/share
	Index term 2	CytoSen Therapeutics–Kiadis: investment, 201904– acquisition merger in shares with 1.94m shares (7.4%) upfront plus 5.82 shares milestones
	Person	Sullivan, Amy (Kiadis 201901– SVP Corporate Affairs before Keryx Biopharmaceuticals + AMAG Pharmaceuticals + Idenix)
	Person 2	Clark, Mary (Optimum Strategic Communications 201710 before Hume Brophy + M:Communications + Capital MSL)

Original document
accessed by [iito] on 2019-05-31

Record changed: 2023-06-05

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x200px

More documents for Kiadis (Group)

[1] SynOx Therapeutics Ltd.. (7/27/21). "Press Release: SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer". Dublin....
[2] Kiadis Pharma N.V.. (11/2/20). "Press Release: Sanofi Offers to Acquire Kiadis for €308 Million". Paris & Amsterdam....
[3] Byondis B.V.. (8/19/20). "Press Release: Byondis Announces Appointment of Chief Financial Officer". Nijmegen....
[4] Kiadis Pharma N.V.. (7/13/20). "Press Release: Kiadis Appoints Ray Barlow, Ph.D. as Chief Business Officer and Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management Team". Amsterdam....
[5] Kiadis Pharma N.V.. (7/8/20). "Press Release: Kiadis Licenses Previously Undisclosed Pre-clinical K-NK-cell Programs to Sanofi, with Total Potential Deal Value of €875 Million, plus Royalties". Amsterdam....
[6] Kiadis Pharma N.V.. (11/12/19). "Press Release: Kiadis Pharma Changes Strategy to Focus Solely on Development of Natural Killer (NK) Cell Therapeutics and Terminates Development of ATIR101". Amsterdam....
[7] Kiadis Pharma N.V.. (10/22/19). "Press Release: Kiadis Pharma Announces Formation of Renowned Scientific Advisory Board". Amsterdam....
[8] Kiadis Pharma N.V.. (10/17/19). "Press Release: Kiadis Pharma Provides Regulatory Update on ATIR101". Amsterdam....
[9] Kiadis Pharma N.V.. (9/10/19). "Press Release: Kiadis Pharma Announces Results for the Six Months Ended June 30, 2019". Amsterdam....
[10] Kiadis Pharma N.V.. (8/19/19). "Press Release: Kiadis Pharma Announces Investor Events for September 2019". Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]